Company Filing History:
Years Active: 1997-2002
Title: The Innovative Contributions of Christophe Lurguin
Introduction
Christophe Lurguin is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research through his innovative patents. With a total of 2 patents, Lurguin's work focuses on methods for cancer screening and the development of specific cytolytic T cells.
Latest Patents
Lurguin's latest patents include a method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules. This invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by the gene MAGE-3. The nonapeptide is presented by the HLA molecule HLA-A1, and the resulting complexes are identified by cytolytic T cells. Such recognition may be utilized in diagnostics or therapeutically. Another patent involves isolated cytolytic T cells specific for complexes of MAGE related peptides, which also utilizes the nonapeptide derived from the tumor rejection antigen precursor encoded by the gene MAGE-3.
Career Highlights
Christophe Lurguin is associated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in cancer diagnostics and therapeutics. His work has the potential to significantly impact the way cancer is diagnosed and treated.
Collaborations
Lurguin collaborates with esteemed colleagues such as Thierry R Boon-Falleur and Pierre Van Der Bruggen, contributing to a rich environment of innovation and research.
Conclusion
Christophe Lurguin's contributions to cancer research through his patents highlight his role as an influential inventor in the field. His innovative methods for cancer screening and the development of specific cytolytic T cells are paving the way for advancements in diagnostics and therapeutics.